ANTXR cell adhesion molecule 2
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The ANTXR2 gene provides instructions for making a protein that is found at the surface of many types of cells. The ANTXR2 protein is believed to interact with components of the extracellular matrix, which is the lattice of proteins and other molecules outside the cell. This matrix strengthens and supports connective tissues, such as skin, bone, cartilage, tendons, and ligaments.
Video picks for GenesVideo library
Normal function
The ANTXR2 gene provides instructions for making a protein that is found at the surface of many types of cells. The ANTXR2 protein is believed to interact with components of the extracellular matrix, which is the lattice of proteins and other molecules outside the cell. This matrix strengthens and supports connective tissues, such as skin, bone, cartilage, tendons, and ligaments.
The ANTXR2 protein is involved in the formation of tiny blood vessels (capillaries). It may also be important for maintaining the structure of basement membranes, which are thin, sheet-like extracellular matrix structures that separate and support cells in many connective tissues. Research suggests that the ANTXR2 protein aids in the breakdown of at least one type of extracellular matrix protein, ensuring the correct balance of proteins is maintained for normal functioning of muscles and connective tissues.
The ANTXR2 protein also acts as a receptor for the toxin that causes anthrax, allowing the toxin to attach to cells and trigger disease.
Conditions referring to this gene or chromosome
Other names
anthrax toxin receptor 2
ANTR2_HUMAN
capillary morphogenesis protein 2
CMG-2
CMG2
FLJ31074
ISH
JHF
MGC111533
MGC45856
Patient picks for Genes

Allergies, blood and immune system
Mastocytosis and mast cell disorders
A mast cell is a type of white blood cell. There are several forms of mastocytosis. In one, there are too many mast cells in the body: in another the number of mast cells is normal but they are too active.
by Dr Laurence Knott

Allergies, blood and immune system
What does the new treatment for sickle cell disease mean for sickle cell patients?
It has been over 20 years since the last breakthrough in the treatment of sickle cell disease. Now a new antibody-based drug has been approved that can significantly reduce the number of episodes of severe pain experienced by patients. What does this step mean for the 15,000 people living with sickle cell disorder in the UK?
by Amberley Davis

Cancer
What to expect during a LLETZ procedure for abnormal cells
Post 25, regular cervical screening is part of many people's medical routine. Often, cervical cells are completely normal and no further action is taken; you're usually asked to come back for another smear test in three years time. But in others, abnormal cells are detected and further treatment is needed. One such treatment is the LLETZ. But what is it, how does it work, and what are its side effects?
by Emily Reynolds

Heart health and blood vessels
Giant Cell Arteritis
Giant cell arteritis is also known as temporal arteritis. The typical symptoms of giant cell arteritis (temporal arteritis) are headache, tenderness over one or both sides of the forehead, and feeling generally unwell. Other symptoms that may occur include pain in your jaw muscles when chewing, and visual loss. Seek medical attention immediately if you suspect that you have giant cell arteritis. People with giant cell arteritis need urgent treatment with steroids. Prompt treatment aims to prevent serious complications such as severe sight impairment which can occur soon after the disease starts.
by Dr Philippa Vincent, MRCGP

Allergies, blood and immune system
Polycythaemia rubra vera
Polycythaemia rubra vera (PRV) is a myeloproliferative disorder, which means the bone marrow makes too many blood cells. It is also sometimes just called polycythaemia (PV). There is an abnormally high number of red blood cells in your blood. You may also have an abnormally high number of platelets and white blood cells.
by Dr Hayley Willacy, FRCGP

Cancer
Stem cell transplant
A stem cell transplant is where blood stem cells (the cells produced by the bone marrow to turn into different types of blood cells) are put back into your body when your bone marrow has been destroyed and cannot make stem cells itself. The bone marrow can be destroyed by diseases such as cancer, chemotherapy or radiotherapy. It is used to increase the chance of a cure or remission if you have a particular type of cancer or blood disorder. It usually involves intense chemotherapy followed by an infusion of stem cells. The treatment requires close nursing and medical care for a number of weeks. Your specialist would advise when the likely benefits of this procedure outweigh the risks.
by Dr Philippa Vincent, MRCGP
Related patient information and medicines

Patient information leaflet
The immune system
This leaflet gives a brief overview of the immune system and how it works. A person with a weak immune system might have difficulty fighting off infections. In autoimmune diseases the body is unable to tell what is its own and what is foreign, so it attacks itself. Autoimmune diseases can attack any part of the body - eg, type 1 diabetes.

Patient information leaflet
Can I take Empagliflozin and Fibre supplements together?
Taking fibre supplements at the same time as empagliflozin might slightly lower the amount of medicine your body absorbs. This could potentially make the empagliflozin less effective at controlling your blood... Our Medicines Interaction Checker helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to.

Patient information leaflet
Throat cancer
Most cases of cancer of the voice box (larynx) occur in people aged over 60. (The throat is usually sprayed with... Dr Krishna Vakharia, 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their.

Patient information leaflet
Can I take Levothyroxine and Fibre supplements together?
Taking fibre supplements at the same time as levothyroxine can stop your body from absorbing the medicine properly. Us... Our Medicines Interaction Checker helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.

Patient information leaflet
Can I take Apixaban and Fibre supplements together?
Taking fibre supplements at the same time as apixaban might lower the amount of medicine your body absorbs. Our Medicines Interaction Checker helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Disclaimer This information is for general educational purposes only and should not be.

Patient information leaflet
Neuroblastoma
Neuroblastoma is a cancer affecting developing nerve cells. Neuroblastoma is a rare cancer and most often occurs in children under 5 years old. Neuroblastoma often starts in the tummy (abdomen) but can spread to other parts of the body, especially bones, liver and skin. The treatments for neuroblastoma include surgery, chemotherapy and.
Further reading and references
- ANTXR cell adhesion molecule 2; MedlinePlus, National Library of Medicine.
- Burgi J, Kunz B, Abrami L, Deuquet J, Piersigilli A, Scholl-Burgi S, Lausch E, Unger S, Superti-Furga A, Bonaldo P, van der Goot FG. CMG2/ANTXR2 regulates extracellular collagen VI which accumulates in hyaline fibromatosis syndrome. Nat Commun. 2017 Jun 12;8:15861. doi: 10.1038/ncomms15861.
- Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. Hum Mutat. 2009 Apr;30(4):583-9. doi: 10.1002/humu.20872.
- Deuquet J, Lausch E, Superti-Furga A, van der Goot FG. The dark sides of capillary morphogenesis gene 2. EMBO J. 2012 Jan 4;31(1):3-13. doi: 10.1038/emboj.2011.442. Epub 2011 Dec 6.
- Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, Martignetti JA. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet. 2003 Oct;73(4):957-66. doi: 10.1086/378781. Epub 2003 Sep 12.
- El-Kamah GY, Fong K, El-Ruby M, Afifi HH, Clements SE, Lai-Cheong JE, Amr K, El-Darouti M, McGrath JA. Spectrum of mutations in the ANTXR2 (CMG2) gene in infantile systemic hyalinosis and juvenile hyaline fibromatosis. Br J Dermatol. 2010 Jul;163(1):213-5. doi: 10.1111/j.1365-2133.2010.09769.x. Epub 2010 Mar 17. No abstract available.
- Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, Morley T, Leppla SH. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12424-9. doi: 10.1073/pnas.0905409106. Epub 2009 Jul 15.
- Rahman N, Dunstan M, Teare MD, Hanks S, Edkins SJ, Hughes J, Bignell GR, Mancini G, Kleijer W, Campbell M, Keser G, Black C, Williams N, Arbour L, Warman M, Superti-Furga A, Futreal PA, Pope FM. The gene for juvenile hyaline fibromatosis maps to chromosome 4q21. Am J Hum Genet. 2002 Oct;71(4):975-80. doi: 10.1086/342776. Epub 2002 Sep 4.
- Shieh JTC, Hoyme HE, Arbour LT. Hyaline Fibromatosis Syndrome. 2008 Feb 27 [updated 2026 Feb 12]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1525/
- Tanaka K, Ebihara T, Kusubata M, Adachi E, Arai M, Kawaguchi N, Utsunomiya J, Miki Y, Hiramoto M, Hattori S, Irie S. Abnormal collagen deposition in fibromas from patient with juvenile hyaline fibromatosis. J Dermatol Sci. 2009 Sep;55(3):197-200. doi: 10.1016/j.jdermsci.2009.06.005. Epub 2009 Jul 9. No abstract available.
- Yan SE, Lemmin T, Salvi S, Lausch E, Superti-Furga A, Rokicki D, Dal Peraro M, van der Goot FG. In-depth analysis of hyaline fibromatosis syndrome frameshift mutations at the same site reveal the necessity of personalized therapy. Hum Mutat. 2013 Jul;34(7):1005-17. doi: 10.1002/humu.22324. Epub 2013 Apr 19.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

